A fatal case of COVID-19 pneumonia due to possible pulmonary thrombosis
Acta Medica Nagasakiensia
; 65(2):67-71, 2021.
Article
in English
| EMBASE | ID: covidwho-1856303
ABSTRACT
The relationship between the severity of COVID-19, hyperinflammation, and intravascular coagulopathy is of critical importance. We report on a case of severe COVID-19 pneumonia treated with favipiravir during the earliest phase of the pandemic. The present case showed improvement in SARS-CoV-2 viral load and the presence of SARS-CoV-2 IgG with decreased radiological evidence of pulmonary infiltration. Moreover, the levels of serum IL-6 and TNF-α did not increase markedly. However, the hypoxia failed to recover, leading to the patient’s death due to possible pulmonary thrombosis, because D-dimer was markedly elevated, and an electrocardiogram showed typical changes. At present, the fact that some COVID-19 patients with mild to moderate symptoms suddenly die at home has become a major issue in Japan. These findings suggest that additional treatment with anti-coagulants should be considered in some COVID-19 patients at risk of hypercoagulation to prevent sudden death from pulmonary thrombosis.
adult; article; blood clotting disorder; case report; clinical article; coronavirus disease 2019; drug therapy; electrocardiogram; electrocardiography; fatality; female; human; human tissue; hypercoagulability; hyperinflammation; hypoxia; Japan; lung infiltrate; male; nonhuman; pandemic; prevention; protein blood level; pulmonary thrombosis; SARS coronavirus 2 immunology test kit; Severe acute respiratory syndrome coronavirus 2; sudden death; virus load; anticoagulant agent; D dimer; endogenous compound; favipiravir; interleukin 6; tumor necrosis factor
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Acta Medica Nagasakiensia
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS